Cargando…

Cancer incidence in type 2 diabetes patients - first results from a feasibility study of the D2C cohort

BACKGROUND: A large prospective study in patients with type 2 diabetes (T2D), the German D2C cohort, is presently being enumerated to investigate risk factors of incident cancer in diabetic patients. STUDY SETTING: A disease management program was offered, on a voluntary basis, to all T2D patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Hense, Hans-Werner, Kajüter, Hiltraud, Wellmann, Jürgen, Batzler, Wolf U
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3152877/
https://www.ncbi.nlm.nih.gov/pubmed/21752291
http://dx.doi.org/10.1186/1758-5996-3-15
_version_ 1782209809640062976
author Hense, Hans-Werner
Kajüter, Hiltraud
Wellmann, Jürgen
Batzler, Wolf U
author_facet Hense, Hans-Werner
Kajüter, Hiltraud
Wellmann, Jürgen
Batzler, Wolf U
author_sort Hense, Hans-Werner
collection PubMed
description BACKGROUND: A large prospective study in patients with type 2 diabetes (T2D), the German D2C cohort, is presently being enumerated to investigate risk factors of incident cancer in diabetic patients. STUDY SETTING: A disease management program was offered, on a voluntary basis, to all T2D patients who were members of a statutory health insurance fund in Germany. This first feasibility report uses data from 26.742 T2D patients, who were 40 to 79 years old, resided in the Muenster District, and who were enrolled between June 2003 and July 2008. Cancer cases were identified through the regional Cancer Registry. METHODS: Invasive cancer cases were identified using probabilistic record linkage procedures and pseudonymised personal identifiers. Censoring date was December 31, 2008. We included only first cancers, leaving 12.650 male and 14.092 female T2D with a total of 88.778 person-years (py). We computed standardised incidence ratios (SIR) for external comparisons and we employed Cox regression models and hazard ratios (HR) within the cohort. RESULTS: We identified 759 first cancers among male T2D patients (18.7 per 1,000 py) and 605 among females (12.7 per 1,000 py). The risk of any incident cancer in T2D was raised (SIR = 1.14; 95% confidence interval [1.10 - 1.21]), in particular for cancer of the liver (SIR = 1.94 [1.15 - 2.94]) and pancreas (SIR = 1.45 [1.07-1.92]). SIRs decreased markedly with time after T2D diagnosis. In Cox models, adjusting for diabetes duration, body mass index and sex, insulin therapy was related to higher cancer risk (HR = 1.25 [1.17 - 1.33]). No effect was seen for metformin. DISCUSSION: Our study demonstrates feasibility of record linkage between DMP and cancer registries. These first cohort results confirm previous reports. It is envisaged to enhance this cohort by inclusion of further regions of the state, expansion of the follow-up times, and collection of a more detailed medication history.
format Online
Article
Text
id pubmed-3152877
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-31528772011-08-10 Cancer incidence in type 2 diabetes patients - first results from a feasibility study of the D2C cohort Hense, Hans-Werner Kajüter, Hiltraud Wellmann, Jürgen Batzler, Wolf U Diabetol Metab Syndr Research BACKGROUND: A large prospective study in patients with type 2 diabetes (T2D), the German D2C cohort, is presently being enumerated to investigate risk factors of incident cancer in diabetic patients. STUDY SETTING: A disease management program was offered, on a voluntary basis, to all T2D patients who were members of a statutory health insurance fund in Germany. This first feasibility report uses data from 26.742 T2D patients, who were 40 to 79 years old, resided in the Muenster District, and who were enrolled between June 2003 and July 2008. Cancer cases were identified through the regional Cancer Registry. METHODS: Invasive cancer cases were identified using probabilistic record linkage procedures and pseudonymised personal identifiers. Censoring date was December 31, 2008. We included only first cancers, leaving 12.650 male and 14.092 female T2D with a total of 88.778 person-years (py). We computed standardised incidence ratios (SIR) for external comparisons and we employed Cox regression models and hazard ratios (HR) within the cohort. RESULTS: We identified 759 first cancers among male T2D patients (18.7 per 1,000 py) and 605 among females (12.7 per 1,000 py). The risk of any incident cancer in T2D was raised (SIR = 1.14; 95% confidence interval [1.10 - 1.21]), in particular for cancer of the liver (SIR = 1.94 [1.15 - 2.94]) and pancreas (SIR = 1.45 [1.07-1.92]). SIRs decreased markedly with time after T2D diagnosis. In Cox models, adjusting for diabetes duration, body mass index and sex, insulin therapy was related to higher cancer risk (HR = 1.25 [1.17 - 1.33]). No effect was seen for metformin. DISCUSSION: Our study demonstrates feasibility of record linkage between DMP and cancer registries. These first cohort results confirm previous reports. It is envisaged to enhance this cohort by inclusion of further regions of the state, expansion of the follow-up times, and collection of a more detailed medication history. BioMed Central 2011-07-13 /pmc/articles/PMC3152877/ /pubmed/21752291 http://dx.doi.org/10.1186/1758-5996-3-15 Text en Copyright ©2011 Hense et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Hense, Hans-Werner
Kajüter, Hiltraud
Wellmann, Jürgen
Batzler, Wolf U
Cancer incidence in type 2 diabetes patients - first results from a feasibility study of the D2C cohort
title Cancer incidence in type 2 diabetes patients - first results from a feasibility study of the D2C cohort
title_full Cancer incidence in type 2 diabetes patients - first results from a feasibility study of the D2C cohort
title_fullStr Cancer incidence in type 2 diabetes patients - first results from a feasibility study of the D2C cohort
title_full_unstemmed Cancer incidence in type 2 diabetes patients - first results from a feasibility study of the D2C cohort
title_short Cancer incidence in type 2 diabetes patients - first results from a feasibility study of the D2C cohort
title_sort cancer incidence in type 2 diabetes patients - first results from a feasibility study of the d2c cohort
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3152877/
https://www.ncbi.nlm.nih.gov/pubmed/21752291
http://dx.doi.org/10.1186/1758-5996-3-15
work_keys_str_mv AT hensehanswerner cancerincidenceintype2diabetespatientsfirstresultsfromafeasibilitystudyofthed2ccohort
AT kajuterhiltraud cancerincidenceintype2diabetespatientsfirstresultsfromafeasibilitystudyofthed2ccohort
AT wellmannjurgen cancerincidenceintype2diabetespatientsfirstresultsfromafeasibilitystudyofthed2ccohort
AT batzlerwolfu cancerincidenceintype2diabetespatientsfirstresultsfromafeasibilitystudyofthed2ccohort